ArticleFrontiers in cardiovascular medicine2025
"One-stop" combined percutaneous left atrial appendage and atrial septal defect closure in atrial fibrillation: safety and feasibility from a single-center cohort.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Very late giant device-related thrombosis on the patent foramen ovale occluder after combined closure of left atrial appendage and patent foramen ovale: a case report and literature review.Journal of geriatric cardiology : JGC · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with atrial fibrillation (AF) and atrial septal defect (ASD) face elevated thromboembolic risks, yet evidence on combined left atrial appendage closure (LAAC) and ASD closure remains limited. We aimed to assess the feasibility and safety of a "one-stop" strategy for simultaneous LAAC and ASD closure. Methods: A retrospective analysis included 40 patients with non-valvular AF and ASD undergoing combined procedures (2016-2024). Procedural success, complications, and long-term outcomes (mean follow-up: 1,194.3 days) were analyzed. Results: All procedures were technically successful. No major complications (stroke, device embolization, or death) occurred during follow-up. Peri-device leak (PDL) was observed in 19 patients (47.5%), with only one case of device-related thrombus (resolved with anticoagulation). Conclusion: The "one-stop" approach is a safe and effective strategy for stroke prevention in AF patients with ASD, particularly those unsuitable for long-term anticoagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.